<DOC>
	<DOCNO>NCT00491790</DOCNO>
	<brief_summary>The purpose study determine montelukast , addition standard treatment helpful treat patient age 2-5 hospital status asthmaticus .</brief_summary>
	<brief_title>Montelukast With Status Asthmaticus , Ages 2-5</brief_title>
	<detailed_description>This prospective study montelukast efficacy addition standard treatment status asthmaticus child 2-5 year old PICU . Children meet eligibility requirement randomize receive rapid-dissolving oral dose montelukast placebo . Once enrol , baseline modify Wood's-Downes clinical asthma severity score record pre post completion standard nebulized albuterol treatment 0.15 mg/kg/dose ( min2.5mg/dose ) . Patients able FEV1 measurement obtain predetermined interval determination clinical asthma severity score . Blood sample PK analysis collect prior study drug administration predetermine time interval determine plasma level montelukast . In addition , blood sample obtain genetic study polymorphism CYP3A4 , CYP3A5 , CYP2C9 .</detailed_description>
	<mesh_term>Status Asthmaticus</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Participant 's parent/legal guardian must give write informed consent prior study participation . When appropriate , write assent child also obtain . Participant , male female , must 2 5 year age . Participant must history reactive airway disease ( RAD ) asthma , must currently admit acute exacerbation RAD asthma . Primary physician must believe patient would benefit improved bronchodilation improvement clinical asthma severity score . Participant must receive standard therapy status asthmaticus : Oxygen need ; 3 nebulized albuterol treatment least 2.5mg/dose ; Methylprednisolone prednisone load dose 2mg/kg ; Ongoing methylprednisolone therapy @ 0.5mg/kg every 6 Known hypersensitivity montelukast Chronic lung disease Cardiac pulmonary congenital anomaly Known renal disease Known hepatic disease Known immunologic disorder allergy atopy Other explanation respiratory distress Use leukotriene modifier within 2 week acute presentation Intubated patient</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>montelukast</keyword>
	<keyword>Albuterol</keyword>
	<keyword>Status Asthmaticus</keyword>
	<keyword>Asthma</keyword>
</DOC>